JP3884581B2 - Acne preventive / ameliorating agent - Google Patents

Acne preventive / ameliorating agent Download PDF

Info

Publication number
JP3884581B2
JP3884581B2 JP28240598A JP28240598A JP3884581B2 JP 3884581 B2 JP3884581 B2 JP 3884581B2 JP 28240598 A JP28240598 A JP 28240598A JP 28240598 A JP28240598 A JP 28240598A JP 3884581 B2 JP3884581 B2 JP 3884581B2
Authority
JP
Japan
Prior art keywords
sphingosine
phosphate
acne
ameliorating agent
phosphoric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP28240598A
Other languages
Japanese (ja)
Other versions
JP2000109409A (en
Inventor
健敏 藤森
幸浩 大橋
和彦 樋口
准子 石川
隆 北原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP28240598A priority Critical patent/JP3884581B2/en
Publication of JP2000109409A publication Critical patent/JP2000109409A/en
Application granted granted Critical
Publication of JP3884581B2 publication Critical patent/JP3884581B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、スフィンゴシン等のリン酸エステル化物を含有するニキビ予防・改善剤及び皮膚外用剤に関する。
【0002】
【従来の技術】
ニキビは、細菌、脂腺機能の亢進、毛嚢孔の角化異常等により形成される。かかるニキビの予防、治療には従来、塩化ベンザルコニウム等の殺菌剤、イオウ、レゾルシン等の角質溶解剤、アラントイン等の消炎剤等が用いられてきた。
【0003】
【発明か解決しようとする課題】
しかし、上記方法はニキビの予防、改善効果が必ずしも十分でなく、さらに優れたニキビの予防・改善剤が望まれていた。
【0004】
【課題を解決するための手段】
本発明者らは、表皮内に存在するスフィンゴシン等のリン酸エステル化物が、ニキビの予防、改善に優れた効果を発揮することを見出した。またかかるリン酸エステル化物が皮膚外用剤として有用であることを見出した。
【0005】
すなわち本発明は、ジヒドロスフィンゴシン、フィトスフィンゴシン、デヒドロスフィンゴシン、デヒドロフィトスフィンゴシン、スフィンガジエニン、及びこれらのN−メチル体またはN,N−ジメチル体から選ばれるスフィンゴシン類(I)のリン酸エステル化物を含有するニキビ予防・改善剤を提供するものである。
【0006】
【発明の実施の形態】
本発明のニキビ予防・改善剤に用いるリン酸エステル化物は、スフィンゴシン類(I)の水酸基の一部または全部をリン酸エステル化したものである。スフィンゴシン類(I)は、スフィンゴシン、ジヒドロスフィンゴシン、フィトスフィンゴシン、デヒドロスフィンゴシン、デヒドロフィトスフィンゴシン、スフィンガジエニン、及びこれらのN−メチル体またはN,N−ジメチル体から選ばれる。スフィンゴシン類(I)のリン酸エステル化物としては、スフィンゴシン−1−リン酸、N−メチルスフィンゴシン−1−リン酸、N,N−ジメチルスフィンゴシン−1−リン酸、フィトスフィンゴシン−1−リン酸、N−メチルフィトスフィンゴシン−1−リン酸、N,N−ジメチルフィトスフィンゴシン−1−リン酸、ジヒドロスフィンゴシン−1−リン酸、N−メチルジヒドロスフィンゴシン−1−リン酸、N,N−ジメチルジヒドロスフィンゴシン−1−リン酸が好ましく、スフィンゴシン−1−リン酸、N−メチルスフィンゴシン−1−リン酸、N,N−ジメチルスフィンゴシン−1−リン酸が特に好ましい。
【0007】
本発明の皮膚外用剤に用いるリン酸エステル化物は、スフィンゴシン類(II)の水酸基の一部または全部をリン酸エステル化したものである。スフィンゴシン類(II)は、スフィンゴシン類(I)からスフィンゴシンを除いたものから選ばれる。
【0008】
上記リン酸エステル化物は、天然型(D(+)体)、非天然型(L(−)体)、またはそれらの混合物のいずれでもよい。また薬学的に許容できる塩が付加したものでもよい。塩としては、ナトリウム塩、カリウム塩等のアルカリ金属塩、カルシウム塩、マグネシウム塩等のアルカリ土類金属塩、あるいは亜鉛塩等が挙げられる。
【0009】
本発明に用いるスフィンゴシン類(I)またはスフィンゴシン類(II)のリン酸エステル化物は例えば、リン酸、五酸化二リン、ポリリン酸、オキシ塩化リン等を用いる一般的なリン酸エステル化法(油化学23,2−8(1974)等)、スフィンゴシルホスホリルコリンにホスホリパーゼDを作用させる方法(J. Biol. Chem. 269, 3181-3188(1994) )、スフィンゴシン等にスフィンゴシンキナーゼを作用させる方法等によって製造できる。また市販品を用いてもよい。
【0010】
本発明の皮膚外用剤は、例えば皮膚の老化防止剤等に用い得る。
【0011】
本発明のニキビ予防・改善剤及び皮膚外用剤は、薬用皮膚外用剤、化粧薬用皮膚外用剤、化粧料等の使用形態にできる。薬用皮膚外用剤及び化粧薬用皮膚外用剤は、例えば上記リン酸エステル化物を含有する軟膏剤が挙げられる。かかる軟膏剤は、動植物油脂等の油性基剤、必要に応じて鎮痛消炎剤、鎮痒剤、殺菌消毒剤、収斂剤、皮膚軟化剤、ホルモン剤等の他の薬効成分を混合し、常法に従い製造できる。また化粧料は、化粧料に一般に用いられる油分、界面活性剤、保湿剤、紫外線吸収剤、アルコール類、キレート類、pH調製剤、防腐剤、増粘剤、色素、香料等を適宜混合し、常法に従い製造できる。化粧料は、乳化化粧料、クリーム、化粧乳液、油性化粧料、ファンデーション、皮膚洗浄剤等にできる。
【0012】
本発明のニキビ予防・改善剤または皮膚外用剤中の、スフィンゴシン類(I)またはスフィンゴシン類(II)のリン酸エステル化物の配合量は、0.001〜10%が好ましく、乳化系の場合は0.001〜5%、特に0.001〜1%が好ましい。
【0013】
【実施例】
試験例1 テトラデカンによる実験的面皰形成に対するスフィンゴシン類(I)のリン酸エステル化物の効果の検討
ニュージーランドホワイトウサギ(雄、体重2.0〜2.5kg)の耳介内側皮膚を試験に使用した。午前中に50%テトラデカン(スクワラン溶液)及び夕方に0.01%の各スフィンゴシン類(I)のリン酸エステル化物(スフィンゴシン−1−リン酸、N,N−ジメチルスフィンゴシン−1−リン酸、フィトスフィンゴシン−1−リン酸及びジヒドロスフィンゴシン−1−リン酸)のエタノール溶液を、それぞれ0.3mLずつ1日1回、2週間連続して塗布した。終了後毛孔一致性の皮疹部(実験的面皰)の面積を、表面顕微鏡を用いて測定した。なお何も塗布しない場合(非塗布群)及び各エタノール溶液の代わりに50%テトラデカンを同様に塗布した場合を対照とした。結果を図1に示す。
【0014】
各スフィンゴシン類(I)のリン酸エステル化物は、実験的面皰の形成を抑制した。
【0015】
実施例1
表1に示す原料中、(1)〜(7)を80℃に加温して均一に混合した後、これに(8)〜(11)を加えて均一に混合し、ニキビ予防・改善剤(W/Oクリーム)を調製した。これは優れたニキビ予防・改善効果を示した。
【0016】
【表1】

Figure 0003884581
【0017】
実施例2
表2に示す各原料を80℃に加温して均一に混合した後冷却し、ニキビ予防・改善剤(軟膏)を調製した。これは優れたニキビ予防・改善効果を示した。
【0018】
【表2】
Figure 0003884581
【0019】
【発明の効果】
本発明のニキビ予防・改善剤は、ニキビの予防・改善に優れた効果を発揮する。
【図面の簡単な説明】
【図1】各スフィンゴシン類(I)のリン酸エステル化物を塗布した場合の、毛孔性皮疹面積を表したものである。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an acne preventing / ameliorating agent and a skin external preparation containing a phosphate ester such as sphingosine.
[0002]
[Prior art]
Acne is formed by bacteria, increased sebaceous gland function, abnormal follicular keratinization, and the like. For the prevention and treatment of acne, bactericides such as benzalkonium chloride, keratolytic agents such as sulfur and resorcin, and anti-inflammatory agents such as allantoin have been used.
[0003]
[Problems to be solved by the invention]
However, the above method is not always sufficient for preventing and improving acne, and an even better acne preventive / ameliorating agent has been desired.
[0004]
[Means for Solving the Problems]
The present inventors have found that a phosphate ester such as sphingosine present in the epidermis exhibits an excellent effect in preventing and improving acne. Moreover, it discovered that this phosphate esterified substance was useful as a skin external preparation.
[0005]
That is, the present invention is phosphoric acid esters of di-hydro sphingosine, phytosphingosine, dehydroepiandrosterone sphingosine, dehydroepiandrosterone phytosphingosine, Fingering diethyl Nin, and their N- methyl derivatives or N, sphingosine selected from N- dimethyl body (I) The present invention provides a preventive / ameliorating agent for acne containing a chemical.
[0006]
DETAILED DESCRIPTION OF THE INVENTION
The phosphoric acid ester used for the acne preventing / ameliorating agent of the present invention is obtained by phosphorylating a part or all of the hydroxyl groups of sphingosine (I). The sphingosines (I) are selected from sphingosine, dihydrosphingosine, phytosphingosine, dehydrosphingosine, dehydrophytosphingosine, sphingadienin, and their N-methyl or N, N-dimethyl isomers. Examples of the phosphoric acid ester of sphingosine (I) include sphingosine-1-phosphate, N-methylsphingosine-1-phosphate, N, N-dimethylsphingosine-1-phosphate, phytosphingosine-1-phosphate, N-methylphytosphingosine-1-phosphate, N, N-dimethylphytosphingosine-1-phosphate, dihydrosphingosine-1-phosphate, N-methyldihydrosphingosine-1-phosphate, N, N-dimethyldihydrosphingosine -1-Phosphoric acid is preferable, and sphingosine-1-phosphate, N-methylsphingosine-1-phosphate, and N, N-dimethylsphingosine-1-phosphate are particularly preferable.
[0007]
The phosphoric acid ester used for the external preparation for skin of the present invention is obtained by phosphorylating a part or all of the hydroxyl groups of sphingosine (II). Sphingosine (II) is selected from sphingosines (I) excluding sphingosine.
[0008]
The phosphoric acid ester product may be a natural type (D (+) form), a non-natural type (L (-) form), or a mixture thereof. In addition, a pharmaceutically acceptable salt may be added. Examples of the salt include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, and zinc salt.
[0009]
The sphingosine (I) or the sphingosine (II) phosphate esterified product used in the present invention is, for example, a general phosphate esterification method (oil oil) using phosphoric acid, diphosphorus pentoxide, polyphosphoric acid, phosphorous oxychloride and the like. Chem. 23, 2-8 (1974), etc.), a method in which phospholipase D is allowed to act on sphingosylphosphorylcholine (J. Biol. Chem. 269, 3181-3188 (1994)), a method in which sphingosine kinase is allowed to act on sphingosine, etc. Can be manufactured. Commercial products may also be used.
[0010]
The external preparation for skin of the present invention can be used, for example, as an anti-aging agent for skin.
[0011]
The acne preventing / ameliorating agent and skin external preparation of the present invention can be used in forms of use such as medicinal skin external preparations, cosmetic skin external preparations, and cosmetics. Examples of the medicinal skin external preparation and the cosmetic skin external preparation include, for example, ointments containing the phosphoric acid ester. Such an ointment is prepared by mixing an oily base such as animal and vegetable fats and oils, an analgesic / anti-inflammatory agent, an antipruritic agent, a disinfectant / disinfectant, an astringent, an emollient, a hormone agent, etc. Can be manufactured. In addition, cosmetics are appropriately mixed with oils, surfactants, moisturizers, ultraviolet absorbers, alcohols, chelates, pH adjusters, preservatives, thickeners, pigments, fragrances and the like commonly used in cosmetics, It can be produced according to a conventional method. Cosmetics can be emulsified cosmetics, creams, cosmetic emulsions, oily cosmetics, foundations, skin cleansing agents and the like.
[0012]
The blending amount of the sphingosine (I) or the sphingosine (II) phosphate ester in the acne prevention / amelioration agent or skin external preparation of the present invention is preferably 0.001 to 10%. 0.001 to 5%, particularly 0.001 to 1% is preferable.
[0013]
【Example】
Test Example 1 Examination of effect of phosphate ester of sphingosine (I) on formation of experimental comedones by tetradecane New pinna white rabbit (male, body weight 2.0-2.5 kg) inner skin of auricle was used for the test. 50% tetradecane (squalane solution) in the morning and 0.01% of each sphingosine (I) phosphate ester (sphingosine-1-phosphate, N, N-dimethylsphingosine-1-phosphate, phyto Each ethanol solution of sphingosine-1-phosphate and dihydrosphingosine-1-phosphate) was applied in an amount of 0.3 mL once a day for two consecutive weeks. After completion, the area of the pore-matched skin eruption (experimental comedones) was measured using a surface microscope. The case where nothing was applied (non-application group) and the case where 50% tetradecane was similarly applied instead of each ethanol solution were used as controls. The results are shown in FIG.
[0014]
Each sphingosine (I) phosphate ester suppressed the formation of experimental comedones.
[0015]
Example 1
In the raw materials shown in Table 1, (1) to (7) are heated to 80 ° C. and uniformly mixed, and then (8) to (11) are added and mixed uniformly to prevent or improve the acne. (W / O cream) was prepared. This showed an excellent acne prevention / improvement effect.
[0016]
[Table 1]
Figure 0003884581
[0017]
Example 2
Each raw material shown in Table 2 was heated to 80 ° C. and mixed uniformly and then cooled to prepare an acne prevention / ameliorating agent (ointment). This showed an excellent acne prevention / improvement effect.
[0018]
[Table 2]
Figure 0003884581
[0019]
【The invention's effect】
The acne preventing / ameliorating agent of the present invention exhibits an excellent effect for preventing and improving acne.
[Brief description of the drawings]
FIG. 1 shows the area of pore eruption when a phosphate ester of each sphingosine (I) is applied.

Claims (1)

ヒドロスフィンゴシン、フィトスフィンゴシン、デヒドロスフィンゴシン、デヒドロフィトスフィンゴシン、スフィンガジエニン、及びこれらのN−メチル体またはN,N−ジメチル体から選ばれるスフィンゴシン類(I)のリン酸エステル化物を含有するニキビ予防・改善剤。 Di hydro sphingosine, phytosphingosine, dehydroepiandrosterone sphingosine, dehydroepiandrosterone phytosphingosine, Fingering diethyl Nin, and acne containing phosphoric acid ester of these N- methyl derivatives or N, sphingosine selected from N- dimethyl body (I) Preventive / improving agent.
JP28240598A 1998-10-05 1998-10-05 Acne preventive / ameliorating agent Expired - Fee Related JP3884581B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP28240598A JP3884581B2 (en) 1998-10-05 1998-10-05 Acne preventive / ameliorating agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28240598A JP3884581B2 (en) 1998-10-05 1998-10-05 Acne preventive / ameliorating agent

Publications (2)

Publication Number Publication Date
JP2000109409A JP2000109409A (en) 2000-04-18
JP3884581B2 true JP3884581B2 (en) 2007-02-21

Family

ID=17651992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP28240598A Expired - Fee Related JP3884581B2 (en) 1998-10-05 1998-10-05 Acne preventive / ameliorating agent

Country Status (1)

Country Link
JP (1) JP3884581B2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020044851A (en) * 2000-12-07 2002-06-19 최승철 Sphingolipid composition for preventing or treating acnes
FR2820037B1 (en) * 2001-01-29 2005-12-09 Dermaconcept Jmc DERMATOLOGICAL COMPOSITION FOR VETERINARY USE COMPRISING A SPHINGOID BASE
FR2820038B1 (en) * 2001-01-29 2004-07-02 Dermaconcept Jmc DERMATOLOGICAL COMPOSITION FOR VETERINARY USE COMPRISING A SPHINGOID BASE
KR100404072B1 (en) * 2001-03-12 2003-11-03 주식회사 두산 Therapeutic composition for broad spectrum dermal disease
FR2823671B1 (en) * 2001-04-23 2004-01-09 Dermaconcept Jmc DERMATOLOGICAL COMPOSITION COMPRISING NICOTINIC ACID OR AN AMIDE, AND A SPHINGOID BASE
US20030072777A1 (en) * 2001-10-05 2003-04-17 Maes Daniel H. Combinatorial anti-acne compositions
KR20030079231A (en) * 2002-04-02 2003-10-10 지앤비코스메틱 Topical cosmetic products which have anti-acne efficacy for the patients with acne and their manufacturing methods.
ITMI20021280A1 (en) * 2002-06-11 2003-12-11 Carlo Ghisalberti ANTI-CELLULITE TREATMENT METHOD
JP2004043358A (en) * 2002-07-11 2004-02-12 Unitika Ltd Treating/preventing agent for acne vulgaris
KR101003532B1 (en) * 2008-08-06 2010-12-28 (주)다미화학 Composition for hair tonic or treating or preventing hair loss
JP5465871B2 (en) * 2008-12-12 2014-04-09 花王株式会社 Acne improver
WO2013015288A1 (en) * 2011-07-26 2013-01-31 ナガセケムテックス株式会社 Lipase activity inhibitor
KR101822154B1 (en) * 2016-06-20 2018-01-26 (주)뷰티화장품 Composition of functional cosmetics and over the counter drugs for treating and improving acne

Also Published As

Publication number Publication date
JP2000109409A (en) 2000-04-18

Similar Documents

Publication Publication Date Title
JP3779733B2 (en) Oxadioic acid and related compounds for the treatment of skin conditions
JP3884581B2 (en) Acne preventive / ameliorating agent
AU731832B2 (en) Method for treatment of dermatological disorders
JPS63192703A (en) External agent for skin
JPH1072334A (en) Oxa-acid for care of skin state and related compound
CA2281430A1 (en) Skin care compositions and their use in healing injured skin
JPH08225427A (en) Composition for make-up or dermatology containing mixture ofceramide and its use for giving dampness to skin
JP2004256471A (en) Emulsion composition
JP2024053124A (en) External Composition
US5723136A (en) Skin activator with glycosaminoglycan production-accelerating effect
KR20070120972A (en) Enhanced delivery of skin benefit agents
JP4430770B2 (en) Skin elasticity improver
JP4828126B2 (en) Antibacterial agent
JP2008231087A (en) Skin preparation for external use
JPWO2011030727A1 (en) External preparation containing panthetin phosphate
JP2003063996A (en) Skin care preparation
JPS63301810A (en) Composition for hair
CA2173172A1 (en) Petroleum jelly with inositol phosphates
JP3568983B2 (en) Hair restorer
JP3470816B2 (en) External preparation for skin
JP6411050B2 (en) Liposomes and cosmetics containing the same
JP4067211B2 (en) Skin preparation
JPH0665053A (en) External preparation for skin
JP3791731B2 (en) Exfoliating agent
JP5900906B2 (en) Method for producing cosmetic base and skin cosmetic

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041020

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20041020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060704

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20061114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20061117

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091124

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101124

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111124

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121124

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121124

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131124

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees